New injection shows promise for tough lymphoma cases
NCT ID NCT07456371
First seen Mar 11, 2026 · Last updated Jun 19, 2026 · Updated 17 times
Summary
This early-stage trial tests a new biologic drug called PIC1 injection in 18 adults with relapsed or refractory B-cell non-Hodgkin lymphoma. The main goal is to check safety and find the right dose. Researchers will also see if the drug can shrink tumors. It is too soon to know if it will work, but it may offer a new option for patients who have run out of standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PIC1 injection (a biologic therapy)
What this could lead to
If successful, this could point toward a new treatment option for patients with hard-to-treat B-cell non-Hodgkin lymphoma.
What could go wrong
This is a very early (Phase 1) and small trial (18 people), so it may not show clear benefit. Side effects are unknown and could be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.